{"nctId":"NCT00079417","briefTitle":"Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma","startDateStruct":{"date":"2005-12-26","type":"ACTUAL"},"conditions":["Intraocular Retinoblastoma"],"count":28,"armGroups":[{"label":"Treatment (chemotherapy, surgery)","type":"EXPERIMENTAL","interventionNames":["Drug: Carboplatin","Procedure: Cryosurgery","Procedure: Infrared Laser Therapy","Radiation: Iodine I-125","Radiation: Radiation Therapy","Radiation: Ruthenium Ru-106","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"Carboplatin","otherNames":["Blastocarb","Carboplat","Carboplatin Hexal","Carboplatino","Carboplatinum","Carbosin","Carbosol","Carbotec","CBDCA","Displata","Ercar","JM-8","Nealorin","Novoplatinum","Paraplatin","Paraplatin AQ","Paraplatine","Platinwas","Ribocarbo"]},{"name":"Cryosurgery","otherNames":["Ablation, Cryo","Cryoablation","cryosurgical ablation"]},{"name":"Infrared Laser Therapy","otherNames":[]},{"name":"Iodine I-125","otherNames":["125-Iodine","I-125","Iodine 125","Iodine I 125"]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]},{"name":"Ruthenium Ru-106","otherNames":["Ru-106","Ruthenium Ru 106"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newly diagnosed Group B intraocular retinoblastoma meeting 1 of the following criteria:\n\n  * Group B tumor(s) in 1 eye\n  * Group B tumor(s) in both eyes\n  * Group A tumor in 1 eye and Group B tumor(s) in the other eye\n  * Group E tumor in 1 eye that has been enucleated and Group B tumor(s) in the remaining eye at the time of enucleation of the Group E tumor\n* Defined by the International Classification System for Intraocular Retinoblastoma as follows:\n\n  * Group A: Small tumors (≤ 3 mm in greatest dimension) confined to the retina, away from foveola and disc meeting the following criteria:\n\n    * More than 3 mm from fovea\n    * More than 1.5 mm from optic disk\n  * Group B: Tumors more than 3 mm meeting the following criteria:\n\n    * Confined to the retina in any location not in Group A\n    * Tumor associated subretinal fluid \\< 3 mm from the tumor margin with no subretinal seeding\n  * Group E: Must have ≥ 1 of the following present:\n\n    * Tumor touching the lens\n    * Tumor anterior to anterior vitreous face involving ciliary body or anterior segment\n    * Diffuse infiltrating retinoblastoma\n    * Neovascular glaucoma\n    * Opaque media from hemorrhage\n    * Tumor necrosis with aseptic orbital cellulites\n    * Phthisis bulbi\n* Confirmation of diagnosis by CT scan or MRI of the brain and orbits AND an ophthalmologic evaluation under anesthesia within the past 3 weeks\n* No choroidal and/or optic nerve invasion past the lamina cribosa\n* No evidence of extraocular retinoblastoma clinically or by head and orbital MRI and/or CT scan\n* No tumor present on histological exam at the cut end of the optic nerve for any Group E eye enucleated before study entry\n* Performance status - ECOG 0-2\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age\n* AST or ALT \\< 2.5 times ULN for age\n* Creatinine clearance (based on Schwartz formula) or radioisotope glomerular filtration rate ≥ 70mL/min/1.73 m\\^2\n* No prior chemotherapy\n* No other concurrent chemotherapy\n* No prior radiotherapy\n* No other concurrent radiotherapy, including intensity-modulated stereotactic, or proton beam radiotherapy\n* Prior enucleation of one eye allowed provided the remaining eye is Group B\n* No concurrent enucleation\n* No prior local ophthalmic therapy for retinoblastoma\n* No other prior therapy for retinoblastoma\n* No local therapy during chemotherapy course 1","healthyVolunteers":false,"sex":"ALL","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival","description":"Proportion of patients with event free survival at 2 years. An event is defined as the need for non-protocol therapy, defined as additional on-protocol chemotherapy, enucleation or external beam radiation, among patients with Group B intraocular tumors with a schedule of neoadjuvant 2-agent (Vincristine/Carboplatin) chemotherapy (chemo-reduction) and standardized local ophthalmic therapy.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate (RR) at Patient Level After the First Course of Therapy","description":"RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy. Number of patients with Type I, II, III or IV response after first course of therapy","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate (RR) at Eye Levels After the First Course of Therapy","description":"RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy. Number eyes with Type I, II, III or IV response after first course of therapy","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival Rate (EFSR) Defined as the Need for Non-protocol Chemotherapy, Enucleation, or EBRT at the Patient Level","description":"EFSR will be estimated for patients who respond to vincristine and carboplatin after an initial 1 cycle of chemoreduction","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0","description":"Participants with Grade 3 and higher reported on protocol therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":21},"commonTop":["Platelet count decreased","Neutrophil count decreased"]}}}